Trastuzumab for gastric cancer Meza-Junco, Au & Sawyer Trastuzumab

Expert Opinion on Biological Therapy

Volumn 9, Issue 12, 2009, Pages 1543-1551

  Meza Junco, Judith ^a   Au, Heather Jane ^a   Sawyer, Michael B ^a  

^a CROSS CANCER INSTITUTE   (Canada)

Author keywords

Gastric cancer; HER 2; Systemic therapy; Trastuzumab

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRIVANIB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LAPATINIB; MATUZUMAB; MECLOFENAMIC ACID; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PLACEBO; SEMAXANIB; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG; VATALANIB;

ADULT RESPIRATORY DISTRESS SYNDROME; ADVANCED CANCER; ALOPECIA; ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; BIOLOGICAL THERAPY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; ESOPHAGUS CANCER; EXTERNAL BEAM RADIOTHERAPY; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOTENSION; INFECTION; INOPERABLE CANCER; LOADING DRUG DOSE; LUNG TOXICITY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIC INFECTION; ONCOGENE NEU; RECURRENT CANCER; REVIEW; RIGOR; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH CANCER; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; PALLIATIVE CARE; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 70450206310     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590903439702     Document Type: Review

References (75)

1. Papers of special note have been highlighted as either of interest (.) or of considerable interest (..) to readers.
2. American Cancer Society: Cancer Facts and Figures 2008. Atlanta, GA: American Cancer Society, 2008. Available from: http://www.cancer.org/docroot/ stt/ content/stt-1x-cancer-facts-and- figures-2008.asp [Last accessed 22 October 2009]
3. Sugano K. Gastric cancer: pathogenesis, screening and treatment. Gastrointest Endocopy Clin N Am 2008;18:513-522
4. Inoue M, Tsugane S. Epidemiology of gastric cancer in Japan. Postgrad Med J 2005;81:419-424
5. Foukakis T, Lundell L, Gubanski M, et al. Advances in the treatment of patients with gastric adenocarcinoma. Acta Oncol 2007;46:277-285 . A review article which includes complete information regarding adjuvant, perioperative and palliative chemotherapy for gastric cancer.
6. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20 . A pivotal Phase III trial that compared peroperatice chemotherapy versus only surgery for gastric cancer, this regimen as considered as a standard in many countries.
7. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730 . A pivotal Phase III trial which compared postoperative chemotherapy versus only surgery for gastric cancer. This regimen as considered as a standard in many countries.
8. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820 . A Phase III trial that showed that S-1 as adjuvant chemotherapy increased overall survival.
9. Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41
10. Pyrhönen S, Kuitunen T, Nyandoto P, et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-591
11. Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-168
12. Janunger KG, Hafström L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 2002;168:597-608 .. A meta-analysis that showed the benefit of chemotherapy for patients with advances gastric cancer.
13. Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-2909 .. A meta-analysis that showed the benefit of chemotherapy for patients with advanced gastric cancer.
14. Cervantes A, Roselló S, Roda D, et al. The treatment of advanced gastric cancer: current strategies and future perspectives. Ann Oncol 2008;19(5S):103-107 .. A review article which include complete information regarding adjuvant, perioperative, palliative chemotherapy and targeted therapy for gastric cancer.
15. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20:1996-2004 (Pubitemid 34413593)
16. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46
17. Van Cutsen E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a Report of the V325 Study Group. J Clin Oncol 2006;24:4991-4997
18. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a Phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: The V-325 Study Group. J Clin Oncol 2007;25:3205-3209 (Pubitemid 47333732)
19. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a Phase III trial for advanced gastric or gastroesophageal adenocarcinoma: The V-325 Study Group. J Clin Oncol 2007;25:3210-3216 (Pubitemid 47325603)
20. Bouché O, Raoul JL, Bonnetain F, et al. Randomized multicenter Phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: A Fé dé ration Francophone de Cancé rologie Digestive Group Study-FFCD 9803. J Clin Oncol 2004;22:4319-4328
21. Moehler M, Eimermacher A, Siebler J, et al. Randomized Phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) versus 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer 2005;92:2122-2128
22. Dank M, Zaluski J, Valvere V, et al. Randomized Phase III trial of irinotecan (CPT 11) 5- FU/folinic acid (FA) vs CDDP-5-FU in first line advanced gastric cancer patients. J Clin Oncol 2005;23(308S):abstract 4003
23. Boku N, Yamamoto S, Shirao K, et al. Randomized Phase III study of 5-fl uorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). Annual Meeting ASCO 2007; abstract LBA4513T
24. Imamura H, IIishi H, Tsuburaya A, et al. Randomized Phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC0301/TOP-002). ASCO Gastrointestinal Symposium 2008; abstract 5
25. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a Phase III trial. Lancet Oncol 2008;9:215-221
26. Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter Phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS). ASCO Gastrointestinal Cancers Symposium 2009; abstract 8
27. Thuss-Patience PC, Kretzschmar A, Deist T, et al. Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized Phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 2009;27(15s):abstract 4540
28. Wilson D, Hiller L, Geh JI. Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol) 2005;17:81-90 . A complete review article which includes many second line chemotherapies for advance gastric cancer.
29. Stathopoulos GP, Rigatos SK, Fountzilas G, et al. Paclitaxel and carboplatin in pretreated advanced gastric cancer: a phase II study. Oncol Rep 2002;9:89-92
30. Cascinu S, Graziano F, Cardarelli N, et al. Phase II study of paclitaxel in pre-treated advanced gastric cancer. Anticancer Drugs 1998;9:307-310
31. Boku N. Chemotherapy for metastatic gastric cancer in Japan. Int J Clin Oncol 2008;13:483-487
32. Arkenau HT. Gastric cancer in the era of molecularly targeted agents: current drug development strategies. J Cancer Res Clin Oncol 2009;135:855-866 .. A complete review article which include several targeted therapies that are been tested in gastric cancer.
33. Ohtsu A. Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol 2008;43:256-264
34. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter Phase II study of irinotecan, cisplatin and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24:5201-5206
35. Enzinger PC, Fidias P, Meyerhardt J, et al. Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer. ASCO Gastrointestinal Cancers Symposium 2006; abstract 68
36. Cohenuram MK, Lacy J. FOLFOX6 and bevacizumab (FOLFOX6/B) for metastatic esophageal (E), gastroesophageal (GE), and gastric (G) adenocarcinoma: a single institution's initial clinical experience. Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, FL, USA, 2008; abstract 74
37. Hammad N, Philip PA, Shields AF, et al. A Phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and gastroesophageal junction (GEJ) cancer. Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, FL, USA, 2008; abstract 30
38. Bang YJ, Kang Y, Kang W, et al. Sunitinib as second line treatment for advanced gastric cancer: preliminary results from a Phase II study. J Clin Oncol 2007;25(18S): abstract 4603
39. Sun W, Powell ME, O'Dwyer P, et al. A Phase II study: combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma (ECOG 5203). J Clin Oncol 2008;26:4535
40. Stein A, Al-Batran SE, Arnold D, et al. Cetuximab with irinotecan as salvage therapy in heavily pretreated patients with metastatic gastric cancer. Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, FL, USA, 2007; abstract 47
41. Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007;18:510-517
42. Lordick F, Lorenzen S, Hegewisch-Becker S, et al. Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter Phase II study of the AIO upper GI study group. J Clin Oncol 2007;25(18S):abstract 4526
43. Woell E, Greil R, Eisterer W, et al. Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer: first results of a multicenter Phase II trial (AGMT Gastric-2). J Clin Oncol 2008;26:15587
44. Tebbutt NC, Sourjina T, Strickland AH, et al. ATTAX2: docetaxel plus cetuximab as second-line treatment for docetaxelrefractory oesophago-gastric cancer-final results of a multicentre Phase II trial by the AGITG. J Clin Oncol 2008;26(20S):abstract 15554
45. Rao S, Starling N, Benson M, et al. Phase I study of the humanized epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with ECX (epirubicin, cisplatin and capecitabine) as first line treatment for advanced oesophagogastric (OG) adenocarcinoma. J Clin Oncol 2005;23(16S):abstract 4028
46. Dragovich T, McCoy S, Fenoglio-Preiser C, et al. SWOG 0127 Phase II trial of erlotinib in GEJ and gastric adenocarcinoma. J Clin Oncol 2006;24:4922-4927
47. Doi T, Koizumi W, Siena S, et al. Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer. Proc Am Soc Clin Oncol 2003;22:abstract 1036
48. Iqbal S, Goldman B, Lenz HJ, et al. A Phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer. J Clin Oncol 2007;25(18S): abstract 4621
49. Baselga J, Swain SM. Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009;9:463-475
50. Halla PS, Cameron DA. Current perspective - Trastuzumab. Eur J Cancer 2009;45(1):12-18 . A review article that describes the main uses of trastuzumab for breast cancer patients.
51. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992;89:4285-4289
52. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007;18:977-984 .. An overview of trastuzumab that focuses on action mechanism and clinical uses.
53. Marty M, Cognetti F, Maraninchi D, et al. Randomized Phase II trial of the efficacy and safety of Trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005;23:4265-4274
54. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792
55. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672
56. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684
57. Smith I, Procter M, Gelber RD, et al. HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36
58. Treish I, Schwartz R, Lindley C. Pharmacology and therapeutic use of trastuzumab in breast cancer. Am J Health Syst Pharm 2000;57:2063-2076
59. Bruno R, Washington CB, Lu JF, et al. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 2005;56:361-369
60. Leyland-Jones B, Gelmon K, Ayoub JP, et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003;21:3965-3971
61. Baselga J, Carbonell X, Castañeda-Soto NJ, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005;23:2162-2171
62. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51 .. An overview of trastuzumab that focuses on action mechanism and clinical uses.
63. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-1221
64. González V, Salgueiro E, Jimeno FJ, et al. Post-marketing safety of antineoplasic monoclonal antibodies: Rituximab and trastuzumab. Pharmacoepidemiol Drug Saf 2008;17:714-721 . An important paper that showed trastuzumab is safe in a post-marketing analysis.
65. Marx AH, Tharun L, Muth J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009;40:769-777
66. Barros-Silva JD, Leitão D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 2009;100:487-493
67. Kim MA, Jung EJ, Lee HS, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol 2007;38:1386-1393
68. Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273-278
69. Yano T, Doi T, Ohtsu A, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006;15:65-71
70. Yu GZ, Chen Y, Wang JJ. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: Their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol 2009;135(10):1331-1339
71. Bang Y, Chung H, Xu J, et al. Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 2009;27(15S):abstract 4556 .. The largest data set of gastric cancer specimens that has been tested for HER2 overexpression.
72. Gong SJ, Jin CJ, Rha SY, et al. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett 2004;214:215-224 .. The first, to our knowledge, preclinical research which showed that trastuzumab is active against gastric cancer.
73. Cortés-Funes H, Rivera F, Alés I, et al. Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/ amplification.
74. -2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(18s):abstract 4613 .. The first, to our knowledge, Phase II trial which showed that trastuzumab is useful to treat patients with gastric cancer.
75. Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: A Phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 2009;27(18s):abstract LBA4509 .. A pivotal Phase III trial that demonstrated improvement in overall survival of patients treated with trastuzumab.